ANI Pharmaceuticals Reports 25.9% Revenue Growth to $266M in Latest Quarter

ANI Pharmaceuticals, Inc. reported significant financial growth in its latest quarterly results, with net revenues reaching $266.0 million for the three months ended June 30, 2026, a 25.9% increase from $211.4 million in the same period last year. The company's operating income also saw a substantial rise, climbing to $40.5 million compared to $13.9 million in the prior year. For the first half of 2026, ANI's net revenues totaled $503.5 million, up 23.3% from $408.5 million in the first half of 2025, driven primarily by strong sales in its Rare Disease and Brands segments.

The growth in revenue was largely attributed to a 30.7% increase in net revenues from the Rare Disease segment, which generated $135.8 million, bolstered by strong sales of Cortrophin Gel. However, sales of ILUVIEN and YUTIQ experienced a decline, with ILUVIEN generating $18.7 million, down 16.1% from the previous year. The Brands segment also faced challenges, with revenues decreasing by 10.5% to $11.8 million. In contrast, the Generics and Other segment reported a 6.8% increase in revenues, totaling $100.7 million, primarily due to new product launches and increased volumes.

In terms of operational developments, ANI Pharmaceuticals has been actively expanding its product offerings and market presence. The company completed the acquisition of Alimera Sciences in September 2024, which added the ILUVIEN and YUTIQ products to its portfolio. The FDA also approved an expanded label for ILUVIEN in March 2025, allowing for its marketing for chronic non-infectious uveitis. The company is focusing on building a dedicated sales organization for Cortrophin Gel, targeting specific patient populations, and plans to continue expanding its Rare Disease business through both organic growth and acquisitions.

As of June 30, 2026, ANI Pharmaceuticals reported total assets of $1.49 billion, with cash and cash equivalents amounting to $360.2 million, up from $285.6 million at the end of 2025. The company’s total liabilities decreased slightly to $896.9 million from $899.7 million. The increase in cash reserves is attributed to strong operational cash flow, which amounted to $115.0 million for the first half of 2026, compared to $110.8 million in the same period of 2025. The company’s outlook remains positive, with expectations of continued revenue growth driven by its strategic initiatives and product expansions, although it acknowledges potential market risks and competition in the pharmaceutical sector.